Compare Arista Networks Inc (ANET) vs Bristol-Myers Squibb Co (BMY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Arista Networks Inc vs Bristol-Myers Squibb Co — how do they compare? Arista Networks Inc trades at $210.85 (market cap $249.53B), while Bristol-Myers Squibb Co trades at $63.77 (market cap $129.94B). The key difference: Arista Networks Inc is the larger of the two by market cap, and Bristol-Myers Squibb Co pays a 3.96% dividend while Arista Networks Inc pays none. Which is the better fit depends on your goals.
| ANET | BMY | |
|---|---|---|
Market Cap | $249.53B | $129.94B |
Sector | Technology | Health |
52-Week High | $197.85 | $65.89 |
52-Week Low | $116.13 | $42.60 |
Enterprise Value | $236.19B | $163.92B |
Dividend Yield | — | 3.96% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Arista Networks (ANET) trades at $208.47, up 8.85% in the last session, reflecting strong momentum amid robust AI-driven demand. The stock shows bullish technical signals with consistent earnings beats and accelerating revenue growth, reaching $9.01B in 2025. Analyst consensus remains overwhelmingly positive with a $252.25 price target, though valuation multiples appear elevated at P/E 62.61 and P/S 23.94. Recent news highlights insider selling but maintains confidence in the company's AI networking leadership.
Outlook remains favorable given hyperscaler capex expansion and Ethernet market share gains, but risks include premium valuation compression and competitive pressures. The stock offers growth exposure to AI infrastructure with solid execution, though investors should weigh high expectations against potential volatility.
Bristol Myers Squibb (BMY) trades at $63.83, down 1.56% today, with strong technical bullish signals and consistent earnings beats. The stock shows robust fundamentals with a 14.01 P/E ratio, 18.87% net margin, and recent $2.3 billion manufacturing investment. Analyst consensus leans neutral with a $68.56 price target, while technical indicators suggest bullish momentum with key support at $63.
BMY presents a balanced opportunity with strong profitability and growth pipeline offset by patent expiration risks. The stock's current valuation appears reasonable with upside potential to analyst targets, though investors should monitor debt levels and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Arista Networks Inc
Arista Networks is a software and hardware provider for the networking solutions sector. Operating as one business unit, software, switching, and router products are targeted for high-performance networking applications, while service revenue comes from technical support. Customer markets include data centers, enterprises, service providers, and campuses. The company is headquartered in Santa Clara, California, and generates most of its revenue in the Americas.
Read more on ANET →About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →
